Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSTRICh trial in poor-risk post-docetaxel metastatic castration-resistant prostate cancer
NL-OMON55594Phase 2Active, not recruiting
- Sponsor
- Netherlands Cancer Institute
- Start
- Jun 2017
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cabazitaxel, abiraterone and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical Benefit Rate. Started Jun 2017; status: active, not recruiting.
02
Drugs
cabazitaxelabirateroneenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON55594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55594.